Drugs / Oral Impact®
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00151671 | Apr 2003 → Apr 2008 | cirrhosis of liver, fibrotic liver disease, hepatocellular carcinoma | Rennes University Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Phase 31 trial | ||||||
| Phase 3 | NCT05726786 | Apr 2023 → Aug 2026 overdue | endometriosis, hemorrhagic cystitis, interstitial cystitis, urinary bladder cancer | Centre Hospitalier Universitaire Vaudois | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00247793 | Jul 1996 → Dec 1998 | cardiac valvular defect | Academic Medical Center - University of Amsterdam | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Oral Impact | “Immunonutrition: Oral Impact®, Nestlé Health Science, Switzerland.” NCT05726786 ↗ |
| Modality | Other / unclassified | “Oral Impact® is a powdered oral feed that provides 309 kcal/bag” NCT05726786 ↗ |
| Route | Oral | “Oral nutritional supplement containing L-arginin, ω3 polyunsaturated fatty acids, and nucleotides.” NCT00151671 ↗ |